Benzodiazepine: An update on their mechanisms of action

Canadian Journal of Clinical Pharmacology

Volumn 3, Issue 2, 1996, Pages 75-82

  Nelson, John ^a   Chouinard, Guy ^b  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b NONE

Author keywords

Agitation; Anxiety; Benzodiazepines; Gammaaminobutyric acid; Insomnia; Psychopharmacology

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; ALPIDEM; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BRETAZENIL; PROTEIN SUBUNIT;

ANXIETY NEUROSIS; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EPILEPSY; HUMAN; HUMAN CELL; HYPNOSIS; INSOMNIA; REVIEW; SEDATION; SLEEP INDUCTION;

EID: 0029759682     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Sternbach LH, Randall LO, Gustafson SR. 1,4-benzodiazepines (chlordiazepoxide and related compounds). In: Gordon M, ed. Psychopharmacological Agents. New York: Academic Press, 1964:137-224.
2. Flory E. An inhibitory and excitatory effect of mammalian central nervous and their action on a single sensory neuron. Arch Int Physiol 1954;62:33-53.
3. Snyder SH. Amino acid neurotransmitters: Biochemical pharmacology In: Tower DB, ed. The Nervous System, vol 1. The Basic Neurosciences. New York: Raven Press, 1975:355-61.
4. Bazemore AW, Elliott KAC, Florey E. Isolation of factor 1. J Neurochem 1957;1:334-9.
5. Pichot P. History of the treatment of anxiety. In: Noyes R Jr, Roth M, Burrows GD, eds. Handbook of Anxiety, vol 4. The Treatment of Anxiety. New York: Elsevier, 1990:3-25.
6. Haefely W, Facklam M, Schoch P, et al. Partial agonists of benzodiazepine receptors for the treatment of epilepsy, sleep, and anxiety disorders. In: Biggio G, Concas A, Costa E, eds. Gabaergic Synaptic Transmission. New York: Raven Press, 1992:379-94.
7. Tamminga CA, Frost JJ. Benzodiazepine-GABAA ionotropic receptors. Am J Psychiatry 1994;151:1408.
8. B receptor antagonists: from synthesis to therapeutic applications. TIPS 1993;14:391-4.
9. Bailey L, Ward M, Musa MN. Clinical pharmacokinetics of benzodiazepines. J Clin Pharmacol 1994;34:804-11.
10. Chouinard G. The use of benzodiazepines in the treatment of manic-depressive illness. J Clin Psychiatry 1988;49(Suppl):15-9.
11. Perry PJ, Garvey MJ, Noyes R Jr. Benzodiazepine treatment of generalized anxiety disorder. In: Noyes R Jr, Roth M, Burrows GD, eds. Handbook of Anxiety, vol 4. The Treatment of Anxiety. New York: Elsevier, 1990:111-24.
12. Sheehan DV, Raj A. Benzodiazepine treatment of panic disorder. In: Noyes R Jr, Roth M, Burrows GD, eds. Handbook of Anxiety, vol 4. The Treatment of Anxiety. New York: Elsevier, 1990:169-206.
13. Chouinard G. Clonazepam in the treatment of bipolar psychotic patients after discontinuation of neuroleptics. Am J Psychiatry 1989;146:1642. (Lett)
14. Bodkin JA. Emerging uses for high-potency benzodiazepines in psychotic disorders. J Clin Psychiatry 1990;51:S41.
15. Wolkowitz OM, Turetsky N, Reus VI, Hargreaves WA. Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. Psychopharmacol Bull 1992;28:291-5.
16. Chouinard G, Annable L, Turnier L, Holobow N, Szkrumelak N. A double-blind randomized clinical trial of rapid tranquillization with IM clonazepam and IM haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry 1993;38:S114-21.
17. Jibiki I, Yamaguchi N. Beneficial effect of the high-dose benzodiazepine derivative clotiazepam on intractable auditory hallucinations in chronic schizophrenic patients. Acta Therapeutica 1993;19:383-8.
18. Ungvari GS, Leung CM, Wong MK, Lau J. Benzodiazepines in the treatment of catatonic syndrome. Acta Psychiatr Scand 1994;89:285-8.
19. Horst WD, Preskorn SH. The role of benzodiazepines in the treatment of psychotic disorders. Psychiat Ann 1993;23:317-24.
20. Harden CL. New antiepileptic drugs. Neurology 1994;44:787-95.
21. Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI. Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab Rev 1983;14:251-92.
22. Harvey SC. Hypnotics and sedatives. In: Goodman Gilman A, Goodman LS, Dall TW, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7th edn. New York: Macmillan Publishing Co, 1985:339.
23. Babbini M, Gaiardi M, Bartoletti M. Anxiolytic versus sedative properties in the benzodiazepine series: differences in structure-activity relationships. Life Sci 1979;25:15-22.
24. Ongini E, Barnett A. Hypnotic specificity of benzodiazepines. Clin Neuropharmacol 1985;8(Suppl 1):517-25.
25. McKenzie SG. Introduction to the pharmacokinetics and pharmacodynamics of benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:623-7.
26. Robertson HA. Evidence for distinct benzodiazepine receptors for anticonvulsant and sedative actions: implications for the treatment of temporal lobe epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:637-40.
27. Kales A, Soldatos CR, Vela-Bueno A. Clinical comparison of benzodiazepine hypnotics with short and long elimination half-lifes. In: Smith DE, Wesson DR, eds. The Benzodiazepines: Current Standards for Medical Practice. Lancaster: MTP Press, 1985.
28. Greenblatt DJ, Shader RI. Long-term administration of benzodiazepines: pharmacokinetic versus pharmacodynamic tolerance. Psychopharmacol Bull 1986;22:416-23.
29. Greenblatt DJ, Friedman HL, Shader RI. Correlating pharmacokinetics and pharmacodynamics of benzodiazepines: problems and assumptions. Psychopharmacology 1987;3:62-71.
30. Ellinwood EH, Nikaido AM, Heatherly DG. Comparative pharmacodynamics of benzodiazepines. Psychopharmacol Ser 1987;3:77-82.
31. Busto UE, Lanctôt KL, Bremner KE, Sellers EM. Benzodiazepine kinetics contribute to their differential abuse. Can J Clin Pharmacol 1995;2:23-8.
32. Teboul E, Chouinard G. A guide to benzodiazepine selection. Part I: pharmacological aspects. Can J Psychiatry 1990;35:700-10.
33. Teboul E, Chouinard G. A guide to benzodiazepine selection. Part II: clinical aspects. Can J Psychiatry 1991;36:62-73.
34. Squires RF, Braestrup C. Benzodiazepine receptors in rat brain. Nature 1977;266:732-7.
35. Möhler H, Okada T. Benzodiazepine receptors: Demonstration in the central nervous system. Nature 1977;198:849-54.
36. Bossmann HB, Case R, Di Stephano P. Diazepam receptor characterization: Specific binding of a benzodiazepine to macromolecules in various areas of rat brain. FEBS Lett 1977;82:368-72.
37. Hommer DW, Skolnick P, Paul SM. The benzodiazepine/GABA receptor complex and anxiety. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987:977.
38. Matsumoto RR. GABA receptors: are cellular differences reflected in function? Brain Res Rev 1989;14:203-25.
39. Haefely W. The biological basis of benzodiazepine actions. In: Smith DE, Wesson DR, eds. The Benzodiazepines: Current Standards for Medical Practice. Lancaster: MTP Press, 1985:7.
40. Kupfesmann I. Hypothalamus and limbic system: Peptidergic neurons, homeostasis, and emotional behavior. In: Kandel ER, Schwartz JH, Jessell TM, eds. Principles of Neural Science, 3rd edn. Norwalk: Appleton & Lange, 1991:735.
41. Lippa AS, Critchett D, Sano MC, et al. Benzodiazepine receptors: cellular and behavioral characteristics. Pharmacol Biochem Behav 1979;10:831-43.
42. Philip BK. Drug reversal: benzodiazepine receptors and antagonists. J Clin Anesth 1993;5:46S-51S.
43. Haefely WE, Martin JR, Richards JG, Schoch P. The multiplicity of actions of benzodiazepine receptor ligands. Can J Psychiatry 1993;38:S102-8.
44. Tallman J, Gallagher DW. The GABA-ergic system - a locus of benzodiazepine action. Ann Rev Neurosci 1985;8:21-44.
45. Haefely WE. Benzodiazepines. Int Anesthesiol Clin 1988;26:262-72.
46. Study RE, Barket JL. Cellular mechanisms of benzodiazepine action. JAMA 1982;247:2147-51.
47. Staley K. Enhancement of the excitatory actions of GABA by barbiturates and benzodiazepines. Neurosci Lett 1992;146:105-7.
48. Potokar J, Nutt DJ. Anxiolytic potential of benzodiazepine receptor partial agonists. CNS Drugs 1994;1:305-7.
49. Galindo A. Effects of procaine pentobarbital and halothane on synaptic transmission in the central nervous system. J Pharmacol Exp Ther 1969;169:185-9.
50. Sieghart W, Karobath M. Molecular heterogeneity of benzodiazepine receptors. Nature 1980;286:285-7.
51. Barnard EA, Darlison MG, Seeburg PH. Molecular biology of the GABAA receptor: the receptor/channel superfamily. Trends Neurosci 1987;10:502-9.
52. B receptor binding sites in mammalian spinal cord. Synapse 1987;1:530-8.
53. B receptors in the central nervous system. Nature 1988;332:156-8.
54. B blocker reduces long-duration inhibition in the neocortex. Eur J Pharmacol 1988;148:485-6.
55. B receptors accelerates amygdala kindling development. Experientia 1992;48:748-51.
56. Zachmann M, Tocci P, Nyhan WL. The occurrence of gamma-aminobutyric acid in human tissues other than brain. J Biol Chem 1966;241:1355-8.
57. Löscher W, Schmidt D. Diazepam increases aminobutyric acid in human cerebrospinal fluid. J Neurochem 1987;49:152-7.
58. Berrettini WH, Nurnberger JI Jr, Hare TA, Simmons-Ailing S, Gershon BS, Post RM. Plasma and CSF GABA in affective illness. Br J Psychiatry 1982;141:483-7.
59. Petty F, Kramer G, Feldman M. Is plasma GABA of peripheral origin? Biol Psychiatry 1987;22:725-32.
60. Petty F, Kramer GL. Stability of plasma GABA with time in healthy controls. Biol Psychiatry 1992;31:743-5.
61. Roy-Byrne PP, Cowley DS, Hommer D, Greenblatt DJ, Kramer GL, Petty F. Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls. Psychopharmacology 1992;109:153-6.
62. Roberts E. GABA in nervous system function - an overview. In: Tower DB, ed. The Nervous System, vol 1. The Basic Neurosciences. New York: Raven Press, 1975:541.
63. Goodchild CS. GABA receptors and benzodiazepines. Br J Anaesth 1993;71:127-33.
64. Davidoff RA. Gamma-aminobutyric acid antagonism and presynaptic inhibition in the frog spinal cord. Science 1972;175:331-3.
65. Guo Z, Gent JP, Goodchild CS. Two GABA mechanisms for spinally mediated antinociception: evidence from antagonism of 5-hydroxytryptamine (5-HT) by bicuculline. Br J Anaesth 1990;64:589P-90P.
66. Castellano C, McGaugh JL. Retention enhancement with post-training picrotoxin: Lack of state dependency. Behav Neurol Biol 1989;51:165-70.
67. McGaugh JL, Castellano C, Brioni J. Picrotoxin enhances latent extinction of conditioned fear. Behav Neurosci 1990;104:264-7.
68. Peduto VA, Concas A, Santoro G, Biggio G, Gessa GL. Biochemical and electrophysiologic evidence that propofol enhances GABAergic transmission in the rat brain. Anesthesiology 1991;75:1000-9.
69. Wesselman JPM, Van Wilgenburg H, Long SK. The effects of pentobarbital and benzodiazepines on GABA-responses in the periphery and spinal cord in vitro. Neurosci Lett 1991;128:261-4.
70. Ashton D, Willems R. In vitro studies on the broad spectrum anticonvulsant loreclezole in the hippocampus. Epilepsy Res 1992;11:75-88.
71. Zaman SH, Shingai R, Harvey RJ, Darlison MG, Barnard EA. Effects of subunit types of the recombinant GABAA receptor on the response to a neurosteroid. Eur J Pharmacol 1992;225:321-30.
72. Greenblatt DJ. Pharmacology of benzodiazepine hypnotics. J Clin Psychiatry 1992;53(Suppl):7-13.
73. Cotariu D, Zaidman JL. Valproic acid and the liver. Clin Chem 1988;34:890.
74. Kalichman MW, Livingston KE, Burnham WM. Pharmacological investigation of gamma aminobutyric acid (GABA) and the development of amygdala-kindled seizures in the rat. Exp Neurol 1981;74:829-36.
75. Halonen T, Pitkänen A, Saano V, Riekkinen PJ. Effects of vigabatrin (gamma-vinyl GABA) on neurotransmission-related amino acids and on GABA and benzodiazepine receptor binding in rats. Epilepsia 1991;32:242-9.
76. Castellano C, Brioni JD, Nagahara AH, McGaugh JL. Post-training systemic and intra-amygdala administration of the GABA-β agonist baclofen impairs retention. Behav Neur Biol 1989;52:170-9.
77. Waldmeier PC, Wicki P, Feldtrauer JJ, Baumann PA. Potential involvement of a baclofen-sensitive autoreceptor in the modulation of release of endogenous GABA from rat brain slices in vitro. NS Arch Pharmacol 1988;337:289-95.
78. Chouinard G. Use of clonazepam in the maintenance treatment of manic depressive illness. In: Proceedings of the IVth World Congress of Biological Psychiatry 1985. New York: Elsevier, 1986:723-6.
79. Fontaine R, Mercier P, Beaudry P, Annable L, Chouinard G. Bromazepam and lorazepam in generalized anxiety: a placebocontrolled study with measurement of drug plasma concentrations. Acta Psychiatr Scand 1986;74:451-8.
80. Chouinard G. Clonazepam in acute and maintenance treatment of bipolar affective disorder. J Clin Psychiatry 1987;48(Suppl):29-36.
81. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-8.
82. Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993;13:257-63.
83. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993;88:1-11.
84. Dinan TG, Leonard BE. Triazolam as safe as other benzodiazepines. BMJ 1993;306:1475-7.
85. Chouinard G. Clonazepam in the treatment of psychiatric disorders. In: McElroy SL, Pope HG, eds. Use of Anticonvulsants in Psychiatry: Recent Advances. Clifton: Oxford Health Care Inc, 1988:43.
86. Epstein FB, Litovitz T. Fatal benzodiazepine toxicity? Am J Emerg Med 1987;5:472. (Lett)
87. Greenblatt DJ, Shader RI, Abernethy DR. Current status of benzodiazepines (second of two parts). N Engl J Med 1983;09:410-6.
88. Marks J. The Benzodiazepines: Use, Overuse, Misuse, Abuse, 2nd edn. Lancaster: MTP Press, 1985:62.
89. Greenblatt DJ, Woo E, Allen MD, Orsulak PJ, Shader RI. Rapid recovery from massive diazepam overdose. JAMA 1978;240:1872-4.
90. Anholt RRH. Mitochondrial benzodiazepine receptors as potential modulators of intermediary metabolism. Trends Pharmacol Sci 1986;7:506.
91. Antkiewicz-Michaluk L, Guidotti A, Kreuger KE. Molecular characterization and mitochondrial density of a recognition site for peripheral-type benzodiazepine ligands. Mol Pharmacol 1988;34:272-8.
92. Basile AS, Skolnick P. Subcellular localization of "peripheraltype" binding sites for benzodiazepines in rat brain. J Neurochem 1986;46:305-8.
93. 3H]PK11195 and autoradiographic localization. Arch Int Pharmacodyn 1983;266:38-49.
94. Davies LP, Huston V. Peripheral benzodiazepine binding sites in heart and their interaction with dipyridamole. Eur J Pharmacol 1981;73:209-11.
95. DeSouza EB, Anholt RRH, Murphy KMM, Snyder SH, Kuhar MJ. Peripheral-type benzodiazepine receptors in endocrine organs: autoradiographic localization in rat pituitary, adrenal and testes. Endocrinology 1985;126:567.
96. Fares F, Bar-Ami S, Brandes JM, Gavish M. Gonadotropin- and estrogen-induced increase of peripheral-type benzodiazepine binding sites in the hypophyseal-genital axis of rats. Eur J Pharmacol 1987;133:97-102.
97. 3H]PK11195, and isoquinoline carboxamide derivative: kinetic studies and autoradiographic localization. J Neurochem 1983;41:1744-50.
98. 3H]PK11195: anatomical and subcellular distribution. Brain Res Bull 1987;18:49-61.
99. McCabe RT, Wamsley JK. Autoradiographic localization of subcomponents of the macromolecular GABA receptor complex. Life Sci 1986;39:1937-45.
100. Ticku MK. Benzodiazepine-GABA receptor-ionophore complex: Current concepts. Neuropharmacology 1983;22:1459-70.
101. Sprengel R, Werner P, Seeburg PH, et al. Molecular cloning and expression of cDNA encoding a peripheral-type benzodiazepine receptor. J Biol Chem 1989;264:20415-21.
102. Krueger KE, Mukhin AG, Antkiewicz-Michaluk L, et al. Purification, cloning, and expression of a peripheral-type benzodiazepine receptor. In: Biggio G, Costa E, eds. GABA and Benzodiazepine Receptor Subtypes. New York: Raven Press, 1990:1.
103. Riond J, Mattei MG, Kaghad M, et al. Molecular cloning and chromosomal localization of a human peripheral-type benzodiazepine receptor. Eur J Biochem 1991;195:305-11.
104. Papadopoulos V, Mukhin AG, Costa E, Krueger KE. The peripheral-type benzodiazepine receptor is functionally linked to Leydig cell steroidogenesis. J Biol Chem 1990;265:3772-9.
105. Papadopoulos V, Berkovich A, Krueger KE. The role of diazepam binding inhibitor and its processing products at mitochondrial benzodiazepine receptors: regulation of steroid biosynthesis. Neuropharmacology 1991;30:1417-23.
106. Amsterdam A, Suh BS. An inducible functional peripheral benzodiazepine receptor in mitochondria of steroidogenic granulosa cells. Endocrinology 1991;129:503-10.
107. Mukhin AG, Papadopoulos V, Costa E, Krueger KE. Mitochondrial benzodiazepine receptors regulate steroid biosynthesis. Proc Natl Acad Sci USA 1989;86:9813-6.
108. Yanagibashi K, Ohno Y, Nakamichi N, et al. Peripheral-type benzodiazepine receptors are involved in the regulation of cholesterol side chain cleavage in adrenocortical mitochondria. J Biochem 1989;106:1026-9.
109. Holmes PV, Drugan RC. Stress-induced regulation of the renal peripheral benzodiazepine receptor: Possible role of the renin-angiotensin system. Psychoneuroendocrinology 1994;19:43.
110. Ferrarese C, Mennini T, Pecora N, et al. Diazepam binding inhibitor (DBI) increases after acute stress in rat. Neuropharmacology 1991;30:1445-52.
111. Holmes PV, Stringer AP, Drugan RC. Impact of psychological dynamics of stress on the peripheral benzodiazepine receptor. Pharmacol Biochem Behav 1992;42:437-44.
112. Holmes PV, Drugan RC. Amygdaloid central nucleus lesions and cholinergic blockade attenuate the response of the renal peripheral benzodiazepine receptor to stress. Brain Res 1993;621:1-9.
113. Philip BK. Flumazenil: the benzodiazepine antagonist. In: Ornstein E, ed. New Drugs in Anesthesia. Philadelphia: WB Saunders, 1993:303.
114. Klotz U, Kanto J. Pharmacokinetics and clinical use of flumazenil. Clin Pharmacokinet 1988;14:1-12.
115. Möhler H, Richards JG. The benzodiazepine receptor: A pharmacologic control element of brain function. Eur J Anaesthesiol 1988;2(Suppl):15-24.
116. Amrein R, Hetzel W, Bonetti EP, Gerecke M. Clinical pharmacology of Dormicum (midazolam) and Anexate (flumazenil). Resuscitation 1988;16:S5-27.
117. Amrein R, Hetzel W. Pharmacology of Dormicum (midazolam) and Anexate (flumazenil). Acta Anaesthesiol Scand 1990:34(Suppl 92):6-15.
118. 11C-] labelled Ro15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. J Psychiatr Res 1985;19:609-22.
119. Gross JB, Weller RS, Conard P. Flumazenil antagonism of midazolam-induced ventilatory depression. Anesthesiology 1991;75:179-85.
120. Geller E, Niv D, Nevo Y, Leykin Y, Sorkin P, Rudick V. Early clinical experience in reversing benzodiazepine sedation with flumazenil after short procedures. Resuscitation 1988;16:S49-56.
121. Pearson RC, McCloy RF, Morris P, Bardhan KD. Midazolam and flumazenil in gastroenterology. Acta Anaesthesiol Scand 1990;34(Suppl 92):21-4.
122. Hommer D, Weingartner H, Breier A. Dissociation of benzodiazepine-induced amnesia from sedation by flumazenil pre-treatment. Psychopharmacology 1993;112:455-60.
123. Schulte, J and Kochs, E. Midazolam and flumazenil in neuroanaesthesia. Acta Anaesthesiol Scand 1990;34(Suppl 92): 96-102.
124. Höjer J, Baehrendtz S, Matell G, Gustafsson LL. Diagnostic utility of flumazenil in coma with suspected poisoning: a double-blind, randomized controlled study. BMJ 1990;301:1308-11.
125. Clausen TG. Wolff J, Carl P, Theilgaard A. The effect of the benzodiazepine antagonist flumazenil on psychometric performance in acute ethanol intoxication in man. Eur J Clin Pharmacol 1990;38:233-6.
126. Rothstein JD, Garland W, Puia G, Guidotti A, Weber RJ, Costa E. Purification and characterization of naturally occurring benzodiazepine receptor ligands in rat and human brain. J Neurochem 1992;58:2102-15.
127. Pena C, Medina JH, Novas ML, Paladini AC, De Robertis E. Isolation and identification in bovine cerebral cortex of n-butyl beta carboline-3-carboxylate, a potent benzodiazepine binding inhibitor. Proc Nat Acad Sci (USA) 1986;83:4952-6.